New antibiotic is effective against gonorrhea, could be first new treatment since 1990s, study says
'Gepotidacin is a novel oral antibacterial treatment with the potential to become an alternative option for the treatment of gonococcal infections, supported by an acceptable safety and tolerability profile,' the researchers wrote in the study published Monday in The Lancet, adding that the drug 'could mark a meaningful advancement in patient care.'
As an antibiotic, gepotidacin works by inhibiting bacteria from replicating in the body. In March, it was approved by the US Food and Drug Administration to treat uncomplicated urinary tract infections in women and girls ages 12 and older. Recurrent UTIs have become a bigger problem as the bacteria that cause them have become more resistant to the antibiotics available to treat them.
Now, there is new hope that gepotidacin may help fight drug-resistant gonorrhea.
'The big takeaway is that having additional treatment options for gonorrhea is fantastic,' said Dr. Jason Zucker, an infectious disease and sexually transmitted infections expert and assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the new study.
Effective treatments for gonorrhea have become increasingly limited in recent years due to the global rise of antimicrobial resistance in Neisseria gonorrhoeae, the bacteria that cause gonorrhea, rendering many previously used first-line antibiotics ineffective.
The current standard of care involves an intramuscular injection of the antibiotic ceftriaxone, which requires a visit to a care facility.
A key benefit of gepotidacin is that it would not involve an injection at the doctor's office, which could make treating gonorrhea more convenient for patients, Zucker said.
'Right now, patients come in, especially if they are not having symptoms, if they test positive, we have to ask them to come back. For some people, that's not so easy,' he said. 'So obviously, the ability to have the pharmacy send treatment to their house, or have them be able to pick it up, would really make things a lot easier for people and reduce the number of doctor visits they have, especially if they have jobs where they don't have a lot of time off.'
Gonorrhea can lead to serious health problems if left untreated, and though rare, can even spread to the blood or joints. Among women, untreated gonorrhea can cause an infection of the reproductive organs called pelvic inflammatory disease, which can lead to a greater risk of pregnancy complications and infertility. In men, gonorrhea also can lead to infertility in rare cases.
In the United States, gonorrhea and other sexually transmitted infections or STIs have become more common. Reported cases of three nationally notifiable STIs – chlamydia, gonorrhea and syphilis – were up 90% in the US in 2023 compared with about two decades prior in 2004, according to data released last year by the US Centers for Disease Control and Prevention. More than 2.4 million cases of STIs were reported in 2023 nationally.
The Phase 3 trial, conducted between October 2019 and October 2023, included more than 600 people ages 12 and older who were diagnosed with gonorrhea in the urogenital area across six countries: Australia, Germany, Mexico, Spain, the United Kingdom and the United States.
The study was funded by the pharmaceutical company GSK, which developed the antibiotic, and the development of gepotidacin was funded in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, and the Defense Threat Reduction Agency, according to GSK.
About half of the study participants were treated with a gepotidacin regimen of two oral doses administered about 10 to 12 hours apart, at 3,000-milligrams per dose. The other participants were provided with the current standard treatment of administering a single dose of the antibiotic ceftriaxone as an injection paired with orally taking the antibiotic azithromycin.
The trial data, which is being presented at the European Society of Clinical Microbiology and Infectious Diseases conference, showed that gepotidacin was as effective as the current leading combination treatment, and was also effective against treatment-resistant infections, which occur when strains of gonorrhea are resistant to currently used antibiotics.
The gonorrhea infections were cured among 92.6% of the study participants who were administered gepotidacin compared with 91.2% of the study participants who were treated with ceftriaxone plus azithromycin.
Among the 7.4% of participants in the gepotidacin group who were not successfully treated, they all were due to missing data, according to GSK, which added that 'in participants with complete data, there was no bacterial persistence at the urogenital body site.'
While the study primarily assessed gepotidacin as a treatment for urogenital gonorrhea, some participants with rectal and throat infections were evaluated. Of those with complete data, the study showed that it was more difficult to treat gonorrhea in the throat compared with other body sites, as 14 out of 16 people with throat gonorrhea and complete data – 88% – were successfully treated.
The researchers wrote that the prevalence of throat infections 'warrants further investigation' in a larger group of participants, as does studying the efficacy of geptodiacin in the treatment of gonorrhea in the throat.
'Pharyngeal gonorrhea is notoriously harder to treat and plays a key role in silent transmission and resistance development, so having reliable oral options at all anatomical sites is critical,' Zucker, said.
The international team of researchers found no life-threatening nor fatal side effects associated with either treatment approach used in the study, but the gepotidacin group had higher rates of side effects compared with the ceftriaxone-plus-azithromycin group, which were mostly gastrointestinal, such as diarrhea and nausea, and almost all were mild or moderate, according to the study.
'One of the challenges is that a lot of oral antibiotics have GI side effects,' Zucker said.
The researchers noted that it will be important to investigate the efficacy of gepotidacin for treating gonorrhea in groups not primarily represented in the study especially women and Black and Brown communities, as 92% of participants in the study were men, 74% were White and 71% were men who have sex with men.
If gepotidacin is approved for the treatment of gonorrhea in the United States, 'the price will be disclosed when the product will be supplied in a market. Our approach would be for it to reflect the value and outcomes they bring to patients, providers and payers while being sensitive to market and societal expectations,' according to a GSK spokesperson.
Bluejepa, the brand name for the version of gepotidacin approved in the United States to treat UTIs, is expected to be available in the second half of 2025.
The new study was 'very well-done' with 'rigorous data,' and having more options to treat gonorrhea is critical for slowing down the bacteria's drug resistance, said Dr. Jeffrey Klausner, a clinical professor of public health at the University of Southern California's Keck School of Medicine in Los Angeles, who was not involved in the trial.
'The more options doctors have to treat gonorrhea means that they do not have to use the same drug over and over again, which is a recipe for disaster and more resistance. We know that using the same drug over and over again leads to drug resistance,' Klausner said in the email. 'If gepotidacin is approved and recommended for gonorrhea treatment, that is a true advance and will greatly help our efforts to slow down drug resistance in gonorrhea.'
In the study, researchers noted that using gepotidacin to treat gonorrhea as an oral treatment option, not an injection, may be more efficient and reduces the risk of persistent, drug-resistant infections.
Yet there is some concern that strains of gonorrhea may eventually develop resistance to gepotidacin, according to a comment paper accompanying the new study in The Lancet.
'In our opinion, N gonorrhoeae will also develop gepotidacin resistance when the selective pressure increases and where compliance to the dual-dose regimen is suboptimal,' Magnus Unemo of Örebro University in Sweden and Teodora Wi of the World Health Organization in Switzerland wrote in the paper.
'Due to the inherent ability of gonococci to develop resistance, difficulties in increasing the gepotidacin dose due to adverse events, and the lack of other treatment options, preclinical and clinical development of additional gonorrhoea treatments remains important,' they wrote. 'In conclusion, gepotidacin is promising for the treatment of gonorrhoea, but the challenges to retain gonorrhoea as a treatable infection will continue.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
a day ago
- Indianapolis Star
Does your energy drink contain booze? Mislabeled Celsius cans included in recall
Celsius energy drinkers might want to check their cans before consuming. Some cans mislabeled as Celsius Astro Vibe Sparkling Blue Razz Edition, a non-alcoholic energy drink, actually contain vodka and were included in High Noon's Beach Variety 12-packs. High Noon said it initiated a recall of the variety packs after it discovered that a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon. The announcement was posted on the US Food and Drug Administration's website. "Consumption of the liquid in these cans will result in unintentional alcohol ingestion," the company said. High Noon said the recalled packs were sent to stores in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin between July 21 and July 23. No illnesses have been reported in connection with the recall at this time, according to High Noon. In an emailed statement to USA TODAY, a spokesperson for High Noon said the company is working with officials to manage the recall. "We are working with the FDA, retailers, and distributors to proactively manage the recall to ensure the safety and well-being of our consumers," the statement reads. The company is advising those who didn't purchase a High Noon Beach variety pack to ensure their Celsius Astro Vibe Sparkling Blue Razz Edition drinks do not contain the lot codes of the recalled products (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) before consuming. Consumers are also advised to throw out the Celsius Astro Vibe Sparkling Blue Razz Edition cans with the impacted lot codes (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) and not drink the liquid, according to the company. High Noon Beach Variety packs with different lot codes than those that are part of the recall are safe to consume, the company added. Anyone who bought the recalled High Noon Beach variety 12-packs or mislabeled Celsius Astro Vibe Sparkling Blue Razz Edition drinks should contact High Noon Consumer Relations at consumerrelations@ to get more information on next steps, including refunds.
USA Today
2 days ago
- USA Today
High Noon recalls vodka seltzers mislabeled as Celsius energy drinks
Some Celsius energy drinkers could have gotten a boozy surprise, leading to a recall, according to an announcement posted on the US Food and Drug Administration's website. According to the announcement, High Noon said it would be recalling its Beach Variety 12-packs after they said some cans were mislabeled as Celsius Astro Vibe Sparkling Blue Razz Edition cans, which are a non-alcoholic energy drink. "Consumption of the liquid in these cans will result in unintentional alcohol ingestion," the company said. High Noon said the mistake was made after some of the Celsius cans were filled with the alcoholic beverage and mislabeled. The company added that the recalled packs were sent to stores in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin between July 21 and July 23. The recall was initiated after High Noon discovered that a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon, the company said. No illnesses have been reported in connection with the recall at this time, according to High Noon. What is High Noon doing to remedy the recalled drinks? In an emailed statement to USA TODAY, a spokesperson for High Noon said the company is working with officials to manage the recall. "We are working with the FDA, retailers, and distributors to proactively manage the recall to ensure the safety and well-being of our consumers," the statement reads. Recalled High Noon drinks lot codes, product description What to do if you bought the recalled drinks The company is advising those who didn't purchase a High Noon Beach variety pack to ensure their Celsius Astro Vibe Sparkling Blue Razz Edition drinks do not contain the lot codes of the recalled products (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) before consuming. Consumers are also advised to throw out the Celsius Astro Vibe Sparkling Blue Razz Edition cans with the impacted lot codes (L CCB 02JL25 2:55 to L CCB 02JL25 3:11) and not drink the liquid, according to the company. High Noon Beach Variety packs with different lot codes than those that are part of the recall are safe to consume, the company added. Anyone who bought the recalled High Noon Beach variety 12-packs or mislabeled Celsius Astro Vibe Sparkling Blue Razz Edition drinks should contact High Noon Consumer Relations at consumerrelations@ to get more information on next steps, including refunds. Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at and follow him on X @fern_cerv_.
Boston Globe
2 days ago
- Boston Globe
Canada's measles outbreak exceeds cases in the US
Alberta, which has low measles vaccine rates, has recorded about 1,600 cases. The largely conservative province has a deep and vocal level of skepticism about the public health system and vaccines, with many people mirroring some of the arguments made in the United States by the health secretary, Robert F. Kennedy Jr. Measles is an airborne virus and one of the world's most infectious diseases, causing flu-like symptoms and a rash. Severe cases can lead to hearing loss, pneumonia, or swelling in the brain. Three people have died in the United States, while in Canada, there has been one death, a premature baby who had contracted the virus in the womb. Advertisement The spread of measles has slowed in Ontario, the province with the largest number of cases. But health professionals say the opposite is true in Alberta, and many are criticizing the provincial government's public health response. 'Our performance is so bad that we have more cases in a population of 5 million than the United States has in a population of 340 million,' said Dr. James Talbot, a former chief medical officer of health in Alberta. Advertisement Vaccination rates among children have fallen globally since the COVID-19 pandemic, according to a study published this month in The Lancet, a medical journal. Canada has been part of the trend. In 2021, 79 percent of children in Canada were vaccinated against measles by their 7th birthday, down from about 86 percent in 2013, according to federal data. But vaccine skepticism in Alberta has become more entrenched in the aftermath of the COVID-19 pandemic, when Canada enforced mandatory vaccination requirements for travel. Alberta became an epicenter of pushback against the mandates, and many of the leaders of protests that paralyzed Ottawa, the country's capital, for weeks came from the province. Unlike Ontario and other provinces, Alberta does not have mandatory immunization requirements for school enrollment. Canada's measles outbreak began in October, in the Atlantic province of New Brunswick and was spread by an international visitor at a Mennonite gathering, according to health officials. That outbreak led to more cases in Ontario, with measles disproportionately affecting Amish, Mennonite, and other Anabaptist communities, according to Dr. Kieran Moore, the province's top doctor. Health officials in Alberta have directly linked some outbreaks to Mennonite communities. The Mennonite faith does not have any doctrine prohibiting vaccinations. But many adherents avoid interacting with the medical system and follow a long tradition of natural remedies. Provincial figures show that about 71 percent of children in Alberta are fully vaccinated by the age of 7. Some of the hardest hit parts of Alberta have immunization rates of less than 50 percent, well below the 95 percent threshold for herd immunity, said Dr. Craig Jenne, a professor at the University of Calgary who studies infectious diseases. Advertisement Several public health experts have criticized the province for its response and are calling on it to declare a public health emergency. 'There's no indication it is slowing or turning around,' Jenne said. 'Clearly, whatever is being done now is not sufficient to bring this back under control.' While health care in Canada is largely the purview of provinces, the federal government has focused on fighting misinformation around measures like vaccinations, said Dr. Howard Njoo, Canada's interim chief public health officer. 'We've learned a lot in terms of how to address, I would say, a trust issue,' Njoo said. Alberta Health Services, the health agency, has placed restrictions on visitors in health care settings used by vulnerable patients, including some cancer wards. To assist with tracing transmissions, local health officials have issued notices in places such as Walmarts, health centers, and grocery stores, where people who were later confirmed to have been infected with measles had gone. But those public alerts have noticeably slowed as health officials have become overwhelmed, said Dr. Lynora Saxinger, an infectious diseases specialist, at a news conference this month organized by the Alberta Medical Association, a nonprofit advocacy group. 'The volume is simply too high for them to be able to catch up,' said Saxinger, adding that an overload of cases will likely also start putting pressure on hospitals. 'We're probably seeing, to some extent, the tip of the iceberg.' This article originally appeared in
